Preclinical data of NKG2D and BCMA CAR-NK cells showed efficacy to eradicate MM cells and clinical trials using CD19 CAR-NK and BCMA CAR-NK are now enrolling (28). This evidence concerns the gene KLRK1 and Miyoshi myopathy.